country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P11918

Copy Link Print Information

D-T7

D-T7 is a transferrin receptor (TfR) binding peptide that mediates brain-targeted delivery. D-T7 acts as a penetration enhancer and uptake promoter for nanoparticles in glioma tissues and target cells. D-T7 can be used in glioma research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 2350190-98-4
Formule: C₄₁H₆₀N₁₄O₉
Masse moléculaire:893.00

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Synthèse personnalisée de peptides

D-T7 Chemical Structure

CAS No.: 2350190-98-4

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

In Vitro

OthersAnti-cancer

Others

D-T7 peptide-modified PEGylated bilirubin nanoparticles (TBRNPs) (0.12-800 μM) exhibit extremely low cytotoxicity against bEnd.3 mouse brain microvascular endothelial cells, with approximately 80% cell viability observed even at concentrations as high as 10 μM^[1].

Anti-cancer

D-T7 peptide-modified CD&PTX co-loaded PEGylated bilirubin nanoparticles (CD&PTX@TBRNPs) exhibit significantly enhanced cytotoxicity against C6 glioma cells after 24 h, with an IC₅₀ of 1.39 μM (CD concentration), which is 8.78-fold lower than that of unmodified CD&PTX@BRNPs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

C6 glioma cells
Concentration:

CD concentrations corresponding to PTX concentrations of 0.2-405 nM
Incubation Time:

24 h
Result:

Achieved an IC₅₀ of 1.39 μM (based on CD concentration), which was 8.78-fold lower than the IC₅₀ of CD&PTX@BRNPs.

In Vivo

Anti-cancerOthers

Anti-cancer

CD&PTX@TBRNPs (modified with D-T7 peptide) (Paclitaxel (HY-B0015) 1.7 mg/kg, intravenous injection; once every 2 days; 6 times total) extends the median survival time of Kunming mice bearing C6 glioma to 53 days, and exhibits superior anti-glioma efficacy and better biocompatibility compared with unmodified nanoparticles and free reagents^[1].

Others

Single-dose D-T7 peptide-modified nanoparticles selectively accumulate in glioma tissues of Kunming mice bearing C6 glioma, and the brain fluorescence intensity at 24 h post-injection is 7.89-fold higher than that of unmodified nanoparticles^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Kunming mice (male, 20 g)^[1]
Dosage:

Paclitaxel 1.7 mg/kg
Administration:

i.v.; every 2 days; 6 doses
Result:

Extended median survival time to 53 days, representing a 231% increase compared to the saline group, and a 23% increase compared to the unmodified CD&PTX@BRNPs group.
Showed the smallest glioma size among all treatment groups.
Exhibited no obvious body weight loss within 20 days of treatment.
Caused no significant toxicity to heart, liver, spleen, lung, or kidney compared to the saline group, with reduced nephrotoxicity relative to free CD&PTX and PTX@BRNPs groups.
Showed hematological parameters mostly within normal ranges, and lower hepatotoxicity than the free CD&PTX group.

Chemical Information

CAS No. 2350190-98-4
Masse moléculaire 893.00
Formule C₄₁H₆₀N₁₄O₉
Sequence

d{HRPYIAH}
Sequence Shortening

d{His-Arg-Pro-Tyr-Ile-Ala-His}
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Instruction de manipulation (2659 KB)

Références

[1]. Yu M, et al. D-T7 Peptide-Modified PEGylated Bilirubin Nanoparticles Loaded with Cediranib and Paclitaxel for Antiangiogenesis and Chemotherapy of Glioma. ACS applied materials & interfaces. 2019 Jan 09;11(1):176-186.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis